U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H48N6O5S2
Molecular Weight 720.944
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RITONAVIR

SMILES

CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4

InChI

InChIKey=NCDNCNXCDXHOMX-XGKFQTDJSA-N
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/norvir-drug.htm https://www.drugs.com/mtm/ritonavir.html http://www.wikidoc.org/index.php/Ritonavir

Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. The most frequently reported adverse drug reactions among patients receiving Ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.

CNS Activity

CNS Penetrant
2432
Curator's Comment: Known to be CNS penetrant in guinea pig and rats. Human data not available.

Originator

Approval Year

1996
210
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
 2.2 µM [IC50]
Inhibitor
8146
 0.14 µM [IC50]
Inhibitor
8146
 0.01 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
NORVIR

Approved Use

KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Clinical Pharmacology (12.4) and Clinical Studies (14)

Launch Date

8.2563839E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11.2 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
129 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RITONAVIR unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Co-administed with::
elvitegravir(125 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
healthy, 29 years
n = 10
Health Status: healthy
Age Group: 29 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Disc. AE: Death fetal...
AEs leading to
discontinuation/dose reduction:
Death fetal (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
50 mg 1 times / day steady, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Co-administed with::
elvitegravir(125 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
healthy, 29 years
n = 10
Health Status: healthy
Age Group: 29 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Disc. AE: Hypertension...
AEs leading to
discontinuation/dose reduction:
Hypertension (grade 2, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
unhealthy, adult
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Other AEs: Gastrointestinal disorder NOS, Lipids abnormal...
Other AEs:
Gastrointestinal disorder NOS
Lipids abnormal
Insulin resistance
Lipoatrophy
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
AEs

AEs

AESignificanceDosePopulation
Death fetal 1 patient
Disc. AE
200 mg 1 times / day steady, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Co-administed with::
elvitegravir(125 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
healthy, 29 years
n = 10
Health Status: healthy
Age Group: 29 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Hypertension grade 2, 1 patient
Disc. AE
50 mg 1 times / day steady, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Co-administed with::
elvitegravir(125 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
healthy, 29 years
n = 10
Health Status: healthy
Age Group: 29 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Gastrointestinal disorder NOS
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
unhealthy, adult
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Insulin resistance
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
unhealthy, adult
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Lipids abnormal
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
unhealthy, adult
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Lipoatrophy
600 mg 2 times / day steady, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
unhealthy, adult
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18815591/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1670
inducer
372

inhibitor
1695
inhibitor
1789
inhibitor
1570

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP3A
208

P-gp
1401

CYP2C19
1410

CYP2E1
846

CYP1A2
1463
CYP3A
188

CYP2D
1

CYP3A5
383
CYP3A
125

CYP1A2
671

CYP2C19
283

CYP2B6
521

UGT
28

P-gp
252
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1620
 no
CYP2E1
929
 no
CYP2D6
1826
 yes [IC50 17.3 uM]
yes (co-administration study)
Comment: A published trial (Aarnoutse et al 2005) cited previously published data that reported a 145% increase in desipramine with ritonavir 500 mg twice daily dosing.
Page: 2.0
CYP2C19
1484
 yes [IC50 23.5 uM]
CYP2C9
1747
 yes [IC50 6.2 uM]
CYP1A2
1620
 yes
CYP2B6
946
 yes
CYP2C19
1484
 yes
CYP2C9
1747
 yes
CYP3A
291
 yes
CYP3A
291
 yes
P-gp
1588
 yes
P-gp
1588
 yes
UGT
55
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A
188
 major
CYP3A4
1670
 yes [Km 0.05 uM]
CYP3A5
383
 yes [Km 0.21 uM]
CYP2D
1
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1603
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:45409
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45409
ChemicalBook
CB0119429
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0119429
MolPort
MolPort-000-883-877
https://www.molport.com/shop/molecule-link/MolPort-000-883-877
Selleck Chemicals
Ritonavir
http://www.selleckchem.com/products/Ritonavir.html
ZINC
ZINC000003944422
http://zinc15.docking.org/substances/ZINC000003944422
eMolecules
877483
https://www.emolecules.com/cgi-bin/more?vid=877483
PubMed

PubMed

TitleDatePubMed
Protease inhibitors shine in triple combinations.
1996 Mar
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
2000 Aug
Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
2000 Dec
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.
2000 Dec 15
In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.
2000 May
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.
2000 Nov 10
Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.
2000 Sep
Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
2001 Apr
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
2001 Apr
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
2001 Apr
Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.
2001 Apr
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
2001 Apr 10
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
2001 Apr 13
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.
2001 Apr 13
Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.
2001 Apr 15
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
2001 Apr 15
[An option even for patients with multiple pretreatment].
2001 Apr 2
[Overcoming weaknesses in therapy. Protease inhibitors with high IQ].
2001 Apr 2
[Possible complication of HIV therapy. Protease inhibitor-induced femur head necrosis].
2001 Apr 2
[Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].
2001 Apr 2
[No resistance even after 1 year. New drug combination against HIV].
2001 Apr 2
[Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV].
2001 Apr 21
Use of HIV protease inhibitors as pharmacoenhancers.
2001 Feb
Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study.
2001 Feb
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.
2001 Feb
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
2001 Feb
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
2001 Feb
Ritonavir-induced carbamazepine toxicity.
2001 Jan
Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.
2001 Jan
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
2001 Jan 26
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
2001 Jan 5
Lopinavir/ritonavir: a protease inhibitor combination.
2001 Jan 8
New developments in anti-HIV chemotherapy.
2001 Jan-Feb
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.
2001 Jun 1
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.
2001 Jun 1
The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
2001 Jun 15
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
2001 Jun 15
A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans.
2001 Mar
Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis.
2001 Mar
Spinal epidural lipomatosis in a human immunodeficiency virus-positive patient receiving steroids and protease inhibitor therapy.
2001 Mar 1
[HIV: a guide on management of seropositive patients].
2001 Mar 3
Lopinavir/ritonavir.
2001 Mar-Apr
Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
2001 May
Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.
2001 May
P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays.
2001 May
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
2001 May 25
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
2001 May 25
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
2001 May 25
[Effective in HIV: dual combination with indinavir and ritonavir].
2001 May 4
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
2001 May 5
Patents

Patents

JP2000515555A
7
JP2001187746A
9
JP2001527517A
8
JP2002503670A
14
JP2002520410A
1
JP2002533470A
11
JP2002536435A
14
JP2002538171A
7
JP2002539246A
18
JP2002544210A
87
JP2003502309A
18
JP2003524620A
19
JP2003528821A
36
JP2003530310A
7
JP2004346077A
7
JP2006511554A
19
JP2006512339A
22
JP2006514917A
60
JP2006515281A
7
JP2006520756A
15
JP2007291131A
1
JP2007503428A
35
JP2007504251A
1
JP2007516260A
16
JP2007519640A
1
JP2007524616A
12
JP2007524644A
48
JP2007536237A
17
JP2008500265A
6
JP2008509742A
25
JP2008510795A
75
JP2009502882A
1
JP2009525265A
19
JP2009531441A
18
JP2010270135A
1
JP2010522142A
15
JP2010536837A
4
JP2011126898A
1
JP2011225524A
1
JP2011506339A
7
JP2011508747A
62
JP2011508748A
30
JP2011508764A
18
JP2011510926A
1
JP2011510927A
1
JP2011528275A
445
JP2011528319A
7
JP2011529864A
7
JP2012500788A
1
JP3592337B2
7
JP4413427B2
14

Sample Use Guides

In Vivo Use Guide
600 mg twice-day with meals. Ritonavir should be started at no less than 300 mg twice daily and increased at 2 to 3 day intervals by 100 mg twice daily.
Route of Administration: Oral
In Vitro Use Guide
Ritonavir diminished the growth rate of Candida albicans as well as the activity of its secreted aspartyl proteinases (Saps) in a nitrogen-limited medium, yeast carbon base and bovine serum albumin (YCB-BSA). This inhibition occurred in a dose-dependent fashion; with 8 mg/l of ritonavir a partial growth inhibition (44%) was produced.
Name Type Language
RITONAVIR
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
NORVIR
Brand Name English
RITONAVIR [VANDF]
Common Name English
RITONAVIR [MI]
Common Name English
VIRITON
Brand Name English
EMPETUS
Brand Name English
PAXLOVID COMPONENT RITONAVIR
Brand Name English
ritonavir [INN]
Common Name English
ABBOTT-84538
Code English
VIEKIRAX COMPONENT RITONAVIR
Brand Name English
RITOVIR
Brand Name English
KALETRA COMPONENT RITONAVIR
Common Name English
RITONAVIR [HSDB]
Common Name English
RITONAVIR [USP-RS]
Common Name English
NSC-693184
Code English
ABT-538
Code English
RITONAVIR COMPONENT OF VIEKIRAX
Brand Name English
RTV
Common Name English
RITONAVIR [EMA EPAR]
Common Name English
RITONAVIR [JAN]
Common Name English
Ritonavir [WHO-DD]
Common Name English
RITONAVIR COMPONENT OF KALETRA
Common Name English
RITONAVIR [ORANGE BOOK]
Common Name English
RITONAVIRUM [WHO-IP LATIN]
Common Name English
A-84538
Code English
RITOMUNE
Brand Name English
RITONAVIR RELATED COMPOUNDS MIXTURE
USP-RS  
Common Name English
2,7,10,12-TETRAAZATRIDECANOIC ACID, 4-HYDROXY-12-METHYL-9-(1-METHYLETHYL)-13-(2-(1-METHYLETHYL)-4-THIAZOLYL)-8,11-DIOXO-3,6-BIS(PHENYLMETHYL)-, 5-THIAZOLYLMETHYL ESTER, (3S,4S,6S,9S)-
Systematic Name English
RITONAVIR [MART.]
Common Name English
2,4,7,12-TETRAAZATRIDECAN-13-OIC ACID, 10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-(2-(1-METHYLETHYL)-4-THIAZOLYL)-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-5-THIAZOLYLMETHYL ESTER (5S-(5R*,8R*,10R*,11R*))-
Common Name English
RITONAVIR [USP IMPURITY]
Common Name English
RITONAVIR [USP MONOGRAPH]
Common Name English
RITONAVIR RELATED COMPOUNDS MIXTURE [USP-RS]
Common Name English
RITONAVIR [WHO-IP]
Common Name English
VIEKIRAX
Brand Name English
5-Thiazolylmethyl [(?S)-?-[(1S,3S)-1-hydroxy-3-[(2S)-2-[3-[(2-isopropyl-4-thiazolyl)methyl]-3-methylureido]-3-methylbutyramido]-4-phenylbutyl]phenethyl]carbamate
Common Name English
RITONAVIR [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548747
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-ATC J05AR10
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-ATC J05AE03
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-VATC QJ05AE03
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
FDA ORPHAN DRUG 549816
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-VATC QJ05AR10
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-ATC J05AP52
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
EMA ASSESSMENT REPORTS LOPINAVIR (AUHTORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-ATC J05AX66
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
NCI_THESAURUS C97366
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
EMA ASSESSMENT REPORTS KALETRA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LPV/R)
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-ATC J05AR23
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-ATC J05AP53
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
NDF-RT N0000191001
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
FDA ORPHAN DRUG 509215
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
NDF-RT N0000175889
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
FDA ORPHAN DRUG 484715
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
NDF-RT N0000000246
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
EMA ASSESSMENT REPORTS VIEKIRAX (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
WHO-ATC J05AX67
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
EMA ASSESSMENT REPORTS NORVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
RITONAVIR
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Description: A white or almost white powder. Solubility: Practically insoluble in water, freely soluble in methanol R, sparingly soluble in acetone R and very slightly soluble in acetonitrile R. Category: Antiretroviral (Protease Inhibitor). Storage: Ritonavir should be kept in a well-closed container, protected from light. Additional information: Ritonavir may exhibit polymorphism. Requirements: Ritonavir contains not less than 98.5 % and not more than 101.0 % of C37H48N6O5S2, calculated with reference to the dried substance.
FDA UNII
O3J8G9O825
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
ChEMBL
CHEMBL163
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
RS_ITEM_NUM
1604803
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
INN
7449
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
EVMPD
SUB10342MIG
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
WIKIPEDIA
RITONAVIR
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
RXCUI
85762
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY RxNorm
NDF-RT
N0000182137
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
NDF-RT
N0000182141
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
NDF-RT
N0000187064
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Cytochrome P450 2B6 Inducers [MoA]
DRUG BANK
DB00503
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
MESH
D019438
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
LACTMED
Ritonavir
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
NDF-RT
N0000185607
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Cytochrome P450 2C19 Inducers [MoA]
DRUG CENTRAL
2391
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
NDF-RT
N0000191266
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Cytochrome P450 1A2 Inducers [MoA]
NDF-RT
N0000190113
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
CHEBI
45409
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
NDF-RT
N0000185507
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Cytochrome P450 2C9 Inducers [MoA]
EPA CompTox
DTXSID1048627
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
NDF-RT
N0000190117
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY UDP Glucuronosyltransferases Inducers [MoA]
NDF-RT
N0000190118
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Cytochrome P450 3A Inducers [MoA]
NSC
693184
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
DAILYMED
O3J8G9O825
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
MERCK INDEX
M9636
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Merck Index
NDF-RT
N0000190114
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
PUBCHEM
392622
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
HSDB
7160
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
IUPHAR
8804
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
NCI_THESAURUS
C1609
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
CAS
155213-67-5
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY P-Glycoprotein Inhibitors [MoA]
USAN
GG-103
Created by admin on Fri Dec 16 17:15:19 UTC 2022 , Edited by admin on Fri Dec 16 17:15:19 UTC 2022
PRIMARY
ACTIVE MOIETY
Structure of RITONAVIR
METABOLITE ACTIVE (PARENT)
Structure of HYDROXYRITONAVIR
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966